Jazz Pharmaceuticals announced a definitive agreement to acquire Actio Biosciences for $820 million upfront to acquire ABS-1230, a potential precision therapy for KCNT1+ epilepsy, which currently has no FDA-approved treatments.
Jazz Pharmaceuticals announced a definitive agreement to acquire Actio Biosciences for $820 million upfront to acquire ABS-1230, a potential precision therapy for KCNT1+ epilepsy, which currently has no FDA-approved treatments.